Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies

Author:

Adams Rebecca1,Osborn Gabriel1,Mukhia Bipashna1,Laddach Roman12,Willsmore Zena1,Chenoweth Alicia13,Geh Jenny L C14,MacKenzie Ross Alastair D4,Healy Ciaran4,Barber Linda5,Tsoka Sophia2,Sanz-Moreno Victoria6,Lacy Katie E1,Karagiannis Sophia N13ORCID

Affiliation:

1. St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UK

2. Department of Informatics, Faculty of Natural, Mathematical & Engineering Sciences, King’s College London, Bush House, London, UK

3. Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s College London, Innovation Hub, Guy’s Hospital, London, UK

4. Department of Plastic Surgery at Guy’s, King’s, and St. Thomas’ Hospitals, London, UK

5. School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Hospital, London, UK

6. Barts Cancer Institute, Queen Mary University of London, London, UK

Funder

Medical Research Council

Cancer Research UK King’s Health Partners Centre at King’s College London

CR UK//NIHR in England/DoH for Scotland

Northern Ireland Experimental Cancer Medicine

Breast Cancer Now

the Guy’s and St Thomas’ Foundation Trust Charity Melanoma Special Fund

Cancer Research UK

the National Institute for Health Research Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Reference133 articles.

1. Euromelanoma. 2020 Melanoma skin cancer report. cited 2021 November 15. Available from: https://www.melanomauk.org.uk/2020-melanoma-skin-cancer-report

2. CRUK. Melanoma skin cancer statistics, cancer research UK February. 2021. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer. Accessed 25 September 2022.

3. Cancer immunotherapy: the beginning of the end of cancer?

4. Advances in Immunotherapy for Melanoma: A Comprehensive Review

5. Current Melanoma Treatments: Where Do We Stand?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3